Establishment and Characterization of a TFE3 -rearranged Renal Cell Carcinoma Cell Line (FU-UR-2) With the PRCC-TFE3 Fusion Transcript
Anticancer Research · 2023
DOI: 10.21873/anticanres.16522 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Masako Ishiguro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology Fukuoka University Hospital, Fukuoka, Japan; mishiguro@fukuoka-u.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology Fukuoka University Hospital, Fukuoka, Japan; mishiguro@fukuoka-u.ac.jp.
- Department of Pathology Fukuoka University Hospital, Fukuoka, Japan.
- Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Zitieren
APA
Ishiguro, M., Fukushige, T., & Iwasaki, H. (2023). Establishment and Characterization of a TFE3 -rearranged Renal Cell Carcinoma Cell Line (FU-UR-2) With the PRCC-TFE3 Fusion Transcript. Anticancer Research. https://doi.org/10.21873/anticanres.16522
Vancouver
Ishiguro M, Fukushige T, Iwasaki H. Establishment and Characterization of a TFE3 -rearranged Renal Cell Carcinoma Cell Line (FU-UR-2) With the PRCC-TFE3 Fusion Transcript. Anticancer Research. 2023. doi:10.21873/anticanres.16522
BibTeX
@article{Ishiguro2023,
author = {Ishiguro, Masako and Fukushige, Tomoko and Iwasaki, Hiroshi},
title = {Establishment and Characterization of a TFE3 -rearranged Renal Cell Carcinoma Cell Line (FU-UR-2) With the PRCC-TFE3 Fusion Transcript},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16522}
}
EUVIMED